Our approach is unique in that we are targeting regulatory T cells (Tregs) to reduce inflammation and slow disease progression. This approach has the potential to be transformative in the treatment of neurodegenerative diseases like ALS, Alzheimer’s, Parkinson’s, and frontotemporal dementia. By focusing on the root cause of these diseases, we believe we can make a significant impact on patients’ lives.
Additionally, our pipeline of preclinical Treg-based investigational therapies shows our commitment to innovation and advancing the field of neurodegenerative disease research. We are not content with the status quo and are constantly pushing the boundaries of what is possible in this challenging space.
Can you tell us more about Coya’s lead candidate, Coya-302, and the upcoming phase 2b trial?
Coya-302 is a promising drug candidate that targets Tregs to reduce inflammation in ALS patients. We are excited to be entering a phase 2b trial sometime in 2025, with top-line results expected in 2026. This trial will be a significant milestone for Coya and could potentially change the landscape of ALS treatment.
We are optimistic about the potential of Coya-302 to improve outcomes for ALS patients and are committed to advancing this groundbreaking therapy through the clinical development process.
What are your goals for Coya in the next few years, and how do you plan to achieve them?
Our ultimate goal at Coya is to become a leading biotech company in the neurodegenerative space. We aim to develop innovative therapies that make a real difference in the lives of patients suffering from these devastating diseases.
Over the next few years, we plan to advance our pipeline of Treg-based therapies for ALS, Alzheimer’s, Parkinson’s, and frontotemporal dementia through clinical development. We will continue to prioritize scientific excellence, patient-centered innovation, and strategic partnerships to drive our success.
By leveraging my experiences in Big Pharma and biotech entrepreneurship, I am confident that we can navigate the challenges ahead and position Coya as a key player in the neurodegenerative disease field.
With a strong financial foundation, a talented team, and a clear vision for the future, I believe that Coya has the potential to make a significant impact on the lives of patients and their families. I am excited about the journey ahead and look forward to seeing the positive outcomes we can achieve together.
Neuroinflammation is a key factor in the development of neurodegenerative diseases, leading to nerve cell death and miscommunication between cells. To address this issue, maintaining regulatory T cell numbers and functionality upstream can be crucial. By targeting multiple pathways in the inflammatory cascade, we can potentially halt the progression of these complex diseases.
At Coya Therapeutics, we believe in the power of combination therapies to tackle neurodegenerative diseases effectively. For example, in ALS, we have combined CTLA4 with low-dose interleukin-2 to target different aspects of the immune system and maintain thyroid function. This approach allows us to address multiple targets simultaneously, increasing the chances of success in treating these devastating conditions.
The market for ALS treatments is ripe for innovation, with a high unmet need for effective therapies. With approximately 30,000 ALS patients in the U.S. and 6,000 new diagnoses each year, there is a significant demand for novel treatment options. Our partnership with Dr. Reddy’s on the commercial side will help us bring our products to market efficiently and reach patients in need.
As a new CEO, my biggest challenge is to ensure that Coya Therapeutics remains focused on our goals, well-funded, and equipped with the resources needed to succeed. We are fortunate to have investors who believe in our scientific approach and are committed to supporting our vision. By staying true to our mission of making neurodegenerative diseases more manageable for patients, we aim to make a lasting impact in the field of biotechnology.
In conclusion, our innovative approach to targeting neuroinflammation and utilizing combination therapies sets us apart in the quest to combat neurodegenerative diseases. With a dedicated team, supportive investors, and a clear vision for the future, we are confident in our ability to make a difference in the lives of patients facing these challenging conditions.
